Department of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine and Medical Center, Beirut, Lebanon.
Department of Radiation Oncology, Faculty of Medicine and Medical Center, Beirut, Lebanon.
FASEB J. 2019 Dec;33(12):14051-14066. doi: 10.1096/fj.201900396RR. Epub 2019 Oct 29.
Cancer was recently annexed to diabetic complications. Furthermore, recent studies suggest that cancer can increase the risk of diabetes. Consequently, diabetes and cancer share many risk factors, but the cellular and molecular pathways correlating diabetes and colon and rectal cancer (CRC) remain far from understood. In this study, we assess the effect of hyperglycemia on cancer cell aggressiveness in human colon epithelial adenocarcinoma cells and in an experimental animal model of CRC. Our results show that Nox (NADPH oxidase enzyme) 4-induced reactive oxygen species (ROS) production is deregulated in both diabetes and CRC. This is paralleled by inactivation of the AMPK and activation of the mammalian target of rapamycin (mTOR) C1 signaling pathways, resulting in 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) accumulation, induction of DNA damage, and exacerbation of cancer cell aggressiveness, thus contributing to the genomic instability and predisposition to increased tumorigenesis in the diabetic milieu. Pharmacologic activation of AMPK, inhibition of mTORC1, or blockade of Nox4 reduce ROS production, restore the homeostatic signaling of 8-oxoguanine DNA glycosylase/8-oxodG, and lessen the progression of CRC malignancy in a diabetic milieu. Taken together, our results identify the AMPK/mTORC1/Nox4 signaling axis as a molecular switch correlating diabetes and CRC. Modulating this pathway may be a strategic target of therapeutic potential aimed at reversing or slowing the progression of CRC in patients with or without diabetes.-Mroueh, F. M., Noureldein, M., Zeidan, Y. H., Boutary, S., Irani, S. A. M., Eid, S., Haddad, M., Barakat, R., Harb, F., Costantine, J., Kanj, R., Sauleau, E.-A., Ouhtit, A., Azar, S. T., Eid, A. H., Eid, A. A. Unmasking the interplay between mTOR and Nox4: novel insights into the mechanism connecting diabetes and cancer.
癌症最近被归入糖尿病并发症。此外,最近的研究表明,癌症会增加患糖尿病的风险。因此,糖尿病和癌症有许多共同的风险因素,但将糖尿病与结肠癌和直肠癌(CRC)相关的细胞和分子途径仍知之甚少。在这项研究中,我们评估了高血糖对人结肠上皮腺癌细胞和 CRC 实验动物模型中癌细胞侵袭性的影响。我们的结果表明,Nox(NADPH 氧化酶)4 诱导的活性氧(ROS)产生在糖尿病和 CRC 中都失调。这与 AMPK 的失活和哺乳动物雷帕霉素靶蛋白(mTOR)C1 信号通路的激活平行,导致 8-氧-7,8-二氢-2'-脱氧鸟苷(8-氧-dG)积累、诱导 DNA 损伤,并加剧癌细胞侵袭性,从而导致基因组不稳定,并增加糖尿病环境中的肿瘤发生倾向。AMPK 的药理学激活、mTORC1 的抑制或 Nox4 的阻断可减少 ROS 的产生,恢复 8-氧鸟嘌呤 DNA 糖苷酶/8-氧-dG 的稳态信号,并减轻糖尿病环境中 CRC 恶性肿瘤的进展。总之,我们的研究结果确定了 AMPK/mTORC1/Nox4 信号轴作为与糖尿病和 CRC 相关的分子开关。调节这条通路可能是一种有治疗潜力的战略靶点,旨在逆转或减缓糖尿病或非糖尿病患者 CRC 的进展。